Your browser is no longer supported. Please, upgrade your browser.
Settings
HZNP Horizon Pharma Public Limited Company daily Stock Chart
HZNP [NASD]
Horizon Pharma Public Limited Company
Index- P/E- EPS (ttm)-3.05 Insider Own0.10% Shs Outstand163.04M Perf Week0.33%
Market Cap2.48B Forward P/E11.72 EPS next Y1.30 Insider Trans0.00% Shs Float162.50M Perf Month1.40%
Income-494.60M PEG- EPS next Q0.22 Inst Own95.50% Short Float8.12% Perf Quarter10.38%
Sales1.09B P/S2.27 EPS this Y-509.50% Inst Trans0.01% Short Ratio6.15 Perf Half Y16.91%
Book/sh6.12 P/B2.49 EPS next Y17.25% ROA-11.60% Target Price18.25 Perf Year-11.16%
Cash/sh3.83 P/C3.97 EPS next 5Y12.90% ROE-44.00% 52W Range9.45 - 17.69 Perf YTD4.18%
Dividend- P/FCF9.15 EPS past 5Y39.30% ROI-2.80% 52W High-14.02% Beta1.46
Dividend %- Quick Ratio1.50 Sales past 5Y169.30% Gross Margin50.20% 52W Low60.95% ATR0.48
Employees980 Current Ratio1.60 Sales Q/Q30.10% Oper. Margin-41.00% RSI (14)56.46 Volatility4.05% 2.90%
OptionableYes Debt/Eq1.90 EPS Q/Q-973.80% Profit Margin-45.30% Rel Volume1.11 Prev Close14.99
ShortableYes LT Debt/Eq1.89 EarningsFeb 05 BMO Payout- Avg Volume2.14M Price15.21
Recom1.90 SMA201.05% SMA505.28% SMA20015.38% Volume2,363,161 Change1.47%
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Oct-31-16Reiterated Mizuho Buy $33 → $29
Sep-13-16Reiterated Mizuho Buy $30 → $33
Jul-11-16Upgrade Morgan Stanley Underweight → Equal-Weight $24
Jun-06-16Initiated Goldman Buy $24
May-10-16Reiterated Mizuho Buy $25 → $24
May-03-16Reiterated Mizuho Buy $34 → $25
Jan-19-16Resumed Jefferies Buy $31
Jan-06-16Resumed Citigroup Neutral
Dec-17-15Initiated Goldman Buy
Dec-14-15Reiterated Mizuho Buy $34 → $36
Jan-15-18 07:30AM  Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC CNW Group
Jan-09-18 03:57PM  U.S. pharma executives expect deals to pick up after tax overhaul Reuters
08:07AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
Jan-08-18 08:32AM  What Does Horizon Pharma Public Limited Companys (NASDAQ:HZNP) Share Price Indicate? Simply Wall St.
07:05AM  Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments GlobeNewswire
07:00AM  Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune GlobeNewswire
Jan-05-18 04:05PM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-04-18 09:17AM  How Analysts Rated Jazz Pharmaceuticals in December Market Realist
07:30AM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
07:30AM  Nuvo Pharmaceuticals Inc. Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® from Piedmont Pharmaceuticals LLC CNW Group
Dec-31-17 03:00PM  3 Top Value Stocks to Buy in 2018 Motley Fool
Dec-28-17 09:21AM  Horizon Pharma Gets FDA Nod for Procysbi Label Expansion Zacks
Dec-27-17 11:21AM  ETFs with exposure to Horizon Pharma Plc : December 27, 2017 Capital Cube
08:35AM  Horizon Pharma shares jump 3% premarket after FDA expands use of treatment for metabolic disorder MarketWatch
08:00AM  Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis GlobeNewswire
03:00AM  Horizon Pharma Shows Improved Relative Price Performance; Still Shy Of Benchmark Investor's Business Daily
Dec-18-17 09:23AM  Horizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:50AM  Free Research Report as Horizon Pharmas Revenue Grew 30.2% ACCESSWIRE
Dec-15-17 03:00AM  Stocks With Rising Relative Price Strength: Horizon Pharma Investor's Business Daily
Dec-14-17 07:30AM  Nuvo Pharmaceuticals Enters into Pennsaid® 2% License Agreement with Gebro Pharma AG for Switzerland and Liechtenstein CNW Group
03:00AM  Horizon Pharma Earns RS Rating Upgrade Investor's Business Daily
Dec-12-17 10:32AM  Analysts Recommendations for BioMarin in December 2017 Market Realist
Dec-05-17 04:05PM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-04-17 11:01AM  ETFs with exposure to Horizon Pharma Plc : December 4, 2017 Capital Cube
Dec-01-17 08:10AM  Todays Research Reports on Stocks to Watch: Horizon Pharma and Insmed Incorporated ACCESSWIRE
Nov-30-17 04:05PM  Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference GlobeNewswire
07:30AM  Nuvo Pharmaceuticals Announces Normal Course Issuer Bid CNW Group
06:00AM  Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer GlobeNewswire
Nov-28-17 07:00AM  Nuvo Pharmaceuticals Commences Trading on the OTCQX® Market in the U.S. CNW Group
Nov-27-17 08:05AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
Nov-24-17 10:42AM  ETFs with exposure to Horizon Pharma Plc : November 24, 2017 Capital Cube
Nov-22-17 05:15PM  Nuvo Pharmaceuticals Announces Appointment of Jesse Ledger as President & Chief Executive Officer CNW Group
08:05AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
Nov-13-17 12:32PM  ETFs with exposure to Horizon Pharma Plc : November 13, 2017 Capital Cube
Nov-10-17 10:00AM  Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017 Capital Cube
09:30AM  Horizon Pharma plc Selected as One of Chicagos Top Workplaces by the Chicago Tribune GlobeNewswire
08:06AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
07:57AM  Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : November 10, 2017 Capital Cube
Nov-08-17 10:40AM  Edited Transcript of HZNP earnings conference call or presentation 6-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 04:05PM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
05:47AM  Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View Zacks
Nov-06-17 12:00PM  Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout GlobeNewswire
09:23AM  Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers TheStreet.com
09:03AM  Horizon (HZNP) Tops Q3 Earnings, Shares Up Zacks
07:27AM  Horizon Pharma reports 3Q loss Associated Press
07:00AM  Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results GlobeNewswire
06:05AM  Horizon Pharma Plc to Host Earnings Call ACCESSWIRE
Nov-05-17 08:51PM  How Financially Strong Is Horizon Pharma Public Limited Company (HZNP)? Simply Wall St.
Nov-04-17 11:00AM  Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age GlobeNewswire
Nov-03-17 11:00AM  Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017 GlobeNewswire
09:19AM  Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX Zacks
Nov-02-17 04:05PM  Horizon Pharma plc to Participate in Investor Conferences in November GlobeNewswire
12:18PM  Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised) Zacks
08:15AM  Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? Zacks
Nov-01-17 05:00PM  Nuvo Pharmaceuticals Announces 2017 Third Quarter Results CNW Group
Oct-26-17 08:00AM  Horizon Pharma plc Announces Availability of PROCYSBI (cysteamine bitartrate) in Canada GlobeNewswire
Oct-25-17 08:00AM  Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease GlobeNewswire
Oct-23-17 08:00AM  Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting GlobeNewswire
Oct-17-17 08:30AM  Horizon Pharma plc Named One of the Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the Second Year in a Row GlobeNewswire
Oct-11-17 11:41AM  ETFs with exposure to Horizon Pharma Plc : October 11, 2017 Capital Cube
Oct-10-17 07:00AM  Horizon Pharma plc to Host Third-Quarter 2017 Conference Call and Webcast on Nov. 6, 2017 GlobeNewswire
Oct-03-17 08:16AM  Horizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : October 3, 2017 Capital Cube
Oct-02-17 06:12PM  Horizon Pharma Public Limited Company (HZNP): How Does It Impact Your Portfolio? Simply Wall St. +6.39%
04:30PM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-28-17 08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and Horizon Pharma ACCESSWIRE
Sep-27-17 10:31AM  ETFs with exposure to Horizon Pharma Plc : September 27, 2017 Capital Cube
Sep-21-17 09:40AM  Is Horizon Pharma (HZNP) A Suitable Pick for Value Investors? Zacks
Sep-19-17 08:01AM  IIROC Trade Halt - Horizon Petroleum Ltd. Newsfile
Sep-15-17 03:44PM  Horizon Pharma weighs sale of primary care unit -sources Reuters
Sep-14-17 10:21AM  Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : September 14, 2017 Capital Cube
Sep-13-17 06:36PM  ETFs with exposure to Horizon Pharma Plc : September 13, 2017 Capital Cube -5.29%
04:05PM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-11-17 01:24PM  Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
08:00AM  Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer GlobeNewswire
Sep-07-17 08:04AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
Sep-05-17 04:05PM  Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-24-17 08:00AM  Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference GlobeNewswire
07:30AM  Nuvo Pharmaceuticals Secures Credit Facility from the Royal Bank of Canada CNW Group
Aug-21-17 06:26PM  Horizon Pharma Plc Value Analysis (NASDAQ:HZNP) : August 21, 2017 Capital Cube
Aug-18-17 08:48AM  Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session Zacks
08:10AM  Today's Research Reports on Stocks to Watch: TherapeuticsMD Inc. and Horizon Pharma ACCESSWIRE
Aug-17-17 03:50PM  Here's Why Horizon Pharma Gained as Much as 13.1% Today Motley Fool +10.51%
Aug-16-17 08:04AM  See what the IHS Markit Score report has to say about Horizon Pharma PLC. Markit
Aug-13-17 11:30AM  Edited Transcript of HZNP earnings conference call or presentation 7-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:04AM  IHS Markit Score upgrades Horizon Pharma PLC to 40 out of 100, despite ranking positively in only one IHS Markit category. Markit
Aug-10-17 09:43AM  Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : August 10, 2017 Capital Cube
08:04AM  IHS Markit Score downgrades Horizon Pharma PLC to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-09-17 05:00PM  Nuvo Pharmaceuticals Announces 2017 Second Quarter Results CNW Group
Aug-08-17 10:05AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View Zacks -7.89%
08:10AM  Todays Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead Pharmaceuticals ACCESSWIRE
Aug-07-17 11:58PM  Horizon Pharma reports 2Q loss Associated Press
11:54AM  Horizon Pharma PLC (HZNP) Q2 Report Sends Shares Surging InvestorPlace
10:41AM  Energy Losses Put Dow's Record-Breaking Streak in Jeopardy TheStreet.com
10:40AM  Horizon Pharma Wins Big in Q2 24/7 Wall St.
09:53AM  Why Horizon Pharma plc Stock Is Rising Today Motley Fool
09:28AM  Stocks to Watch: Brighthouse, Berkshire Hathaway, Tesla, Horizon Pharma The Wall Street Journal
09:27AM  Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher TheStreet.com
08:43AM  Morning Movers: Tyson Jumps, Horizon Soars, Teva Tumbles Barrons.com
Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walbert Timothy PChairman, President and CEOJan 02Option Exercise0.0049,5000497,701Jan 03 06:25 PM
GREY MICHAEL GDirectorMay 10Buy9.4810,00094,80025,448May 10 07:22 PM
Carey RobertEVP, Chief Business OfficerMar 01Sale16.0030,000480,00095,408Mar 02 06:40 PM
Carey RobertEVP, Chief Business OfficerFeb 28Sale16.481,80829,796125,408Mar 02 06:40 PM